A National Translational Science Network of Precision-Based Immunotherapy for Primary Liver Cancer (PLC)

The primary objective of the NCI-CLARITY study is to establish a biospecimen repository for genomic, genetic and epigenetic analysis to study the biology of primary liver cancer (PLC) development and progression. Secondary objectives include predicting overall and progression-free survival following immunotherapy. In the retrospective phase, anonymous archival tissue from PLC patients was obtained from five participating sites. Whole exome and transcriptome sequencing was generated and used to predict overall survival in response to immunotherapy.]]>
Inclusion criteria:Patients with histological/ultrasound/imaging confirmed or suspicious lesion of HCC or CCAPatients with planned or a history of at least 1 dose of immunotherapy for HCC or CCAAbility of subject or Legally Authorized Representative to understand and the willingness to sign a written informed consent document.Age greater than or equal to 18 years old at date of study consentExclusion criteria:Patients with known HIV infection]]>